Protara Therapeutics (TARA) Long-Term Investments (2021 - 2026)

Protara Therapeutics' Long-Term Investments history runs 5 years deep, the most recent figure standing at $41.6 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 25.6% year-over-year to $41.6 million; the TTM figure through Mar 2026 stood at $41.6 million (up 25.6% YoY), while the FY2025 annual figure was $42.3 million, changed N/A from the prior year.
• Long-Term Investments was $41.6 million for Q1 2026 at Protara Therapeutics, down from $42.3 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $42.3 million in Q4 2025 to a low of $957000.0 in Q3 2025.
• Historically, Long-Term Investments has averaged $21.8 million across 4 years, with a median of $20.6 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Long-Term Investments sank 90.63% in 2023, then grew 25.6% in 2026.
• A 4-year view of Long-Term Investments shows it stood at $17.9 million in 2022, then sank by 83.83% to $2.9 million in 2023, then soared by 1363.39% to $42.3 million in 2025, then decreased by 1.64% to $41.6 million in 2026.
• The last three Long-Term Investments figures came in at $41.6 million (Q1 2026), $42.3 million (Q4 2025), and $957000.0 (Q3 2025), per Business Quant data.